Cargando…
TCR-like antibodies in cancer immunotherapy
Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antib...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744646/ https://www.ncbi.nlm.nih.gov/pubmed/31521180 http://dx.doi.org/10.1186/s13045-019-0788-4 |
_version_ | 1783451413991391232 |
---|---|
author | He, Qinghua Liu, Zhaoyu Liu, Zhihua Lai, Yuxiong Zhou, Xinke Weng, Jinsheng |
author_facet | He, Qinghua Liu, Zhaoyu Liu, Zhihua Lai, Yuxiong Zhou, Xinke Weng, Jinsheng |
author_sort | He, Qinghua |
collection | PubMed |
description | Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries. |
format | Online Article Text |
id | pubmed-6744646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67446462019-09-18 TCR-like antibodies in cancer immunotherapy He, Qinghua Liu, Zhaoyu Liu, Zhihua Lai, Yuxiong Zhou, Xinke Weng, Jinsheng J Hematol Oncol Review Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries. BioMed Central 2019-09-14 /pmc/articles/PMC6744646/ /pubmed/31521180 http://dx.doi.org/10.1186/s13045-019-0788-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review He, Qinghua Liu, Zhaoyu Liu, Zhihua Lai, Yuxiong Zhou, Xinke Weng, Jinsheng TCR-like antibodies in cancer immunotherapy |
title | TCR-like antibodies in cancer immunotherapy |
title_full | TCR-like antibodies in cancer immunotherapy |
title_fullStr | TCR-like antibodies in cancer immunotherapy |
title_full_unstemmed | TCR-like antibodies in cancer immunotherapy |
title_short | TCR-like antibodies in cancer immunotherapy |
title_sort | tcr-like antibodies in cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744646/ https://www.ncbi.nlm.nih.gov/pubmed/31521180 http://dx.doi.org/10.1186/s13045-019-0788-4 |
work_keys_str_mv | AT heqinghua tcrlikeantibodiesincancerimmunotherapy AT liuzhaoyu tcrlikeantibodiesincancerimmunotherapy AT liuzhihua tcrlikeantibodiesincancerimmunotherapy AT laiyuxiong tcrlikeantibodiesincancerimmunotherapy AT zhouxinke tcrlikeantibodiesincancerimmunotherapy AT wengjinsheng tcrlikeantibodiesincancerimmunotherapy |